drugset / Trial / NCT01169909
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
NaSingle-groupOpen-labelTreatment
Summary
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
Timeline
- Start
- 2010-08
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Other |
| Subject | Ranibizumab | Monoclonal antibody | 2 mg | Other |